Might want to forecast the cash flows and add a CAGR, google that and apply the DCF model to it for a start, hope to hear your response in another month when you figure it out. Oh, and don't forget to apply the ART forecast into it. I'm sure large pharma isn't interested in the current state but rather the Elite with 15 ART's. Because, if large pharma was interested in the 150% YOY growth in earnings, we'd be bought out already.
The CEO himself said $4--$5 on one ADT. And then he said there would be many more ADTs! He said this to Couch at the important conference (whose name i've forgotten) that put ELTP in front of a lot of important people.
News 
Market Data 
Discover 
AI
